School of Medicine
Showing 21-40 of 54 Results
-
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.
-
Stephen J. Galli, MD
Mary Hewitt Loveless, MD, Professor in the School of Medicine and Professor of Pathology and of Microbiology and Immunology
On Partial Leave from 10/01/2024 To 12/05/2024Current Research and Scholarly InterestsThe goals of Dr. Galli's laboratory are to understand the regulation of mast cell and basophil development and function, and to develop and use genetic approaches to elucidate the roles of these cells in health and disease. We study both the roles of mast cells, basophils, and IgE in normal physiology and host defense, e.g., in responses to parasites and in enhancing resistance to venoms, and also their roles in pathology, e.g., anaphylaxis, food allergy, and asthma, both in mice and humans.
-
Chris Garcia
Younger Family Professor and Professor of Structural Biology
Current Research and Scholarly InterestsStructural and functional studies of transmembrane receptor interactions with their ligands in systems relevant to human health and disease - primarily in immunity, infection, and neurobiology. We study these problems using protein engineering, structural, biochemical, and combinatorial biology approaches.
-
Rogelio A. Hernández-López
Assistant Professor of Bioengineering and of Genetics
Current Research and Scholarly InterestsOur group works at the interface of mechanistic, synthetic, and systems biology to understand and program cellular recognition, communication, and organization. We are currently interested in engineering biomedical relevant cellular behaviors for cancer immunotherapy.
-
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsClinical research in allogeneic and autologous hematopoietic cell transplantation (HCT), more specifically, allogeneic transplantation and graft versus host disease. Exploring methods of improving prevention and treatment of GVHD as well as the long term follow-up and/or quality of life of affected patients.
-
Amanda Kirane, MD, PhD, FACS, FSSO
Assistant Professor of Surgery (General Surgery)
BioDr. Kirane is a fellowship-trained, board-certified specialist in complex general surgical oncology. She is an Assistant Professor in the Department of Surgery, Section of Surgical Oncology, at Stanford University School of Medicine. Dr. Kirane serves as Director of Cutaneous Surgical Oncology at the Stanford Cancer Center and her clinical practice focuses on the diagnosis and treatment of melanoma and other skin cancers. She partners closely with patients and families to provide the most effective treatment approach possible. For each patient, she tailors an evidence-based, personalized care plan that is innovative, comprehensive, and compassionate.
Dr. Kirane is Principal Investigator of multiple studies in melanoma and mechanisms of resistance to immunotherapy, with focus on myeloid biology. Her current interests include immune response and novel therapies in melanoma, predictive modeling of patient responses using organoid technology, and translational biomarker development. She has led research into immune therapy for earlier stage melanoma using regionally directed therapy to augment immune response in melanoma and trials in surgical care in melanoma.
The National Institutes of Health, American Society of Clinical Oncology, the Melanoma Research Alliance, and others have funded her research. She has co-authored articles on her discoveries in the Journal of Clinical Investigation, Nature Communications, Nature Genetics, Cancer Research, Journal of Surgical Oncology, Annals of Surgery, Annals of Surgical Oncology, and elsewhere. Topics include intratumoral therapy, biomarker development, macrophage biology in melanoma and immunotheraputic resistance, and patient-derived organoid modeling. Dr. Kirane has presented updates on the management of melanoma and other cancers to her peers at meetings of the American College of Surgeons, Society of Surgical Oncology, and Society for Immunotherapy in Cancer.
Dr. Kirane has earned awards for her achievements in clinical care, research, and scholarship. The Society for Immunotherapy of Cancer, Society of Surgical Oncology, Memorial Sloan Kettering Cancer Center, and other prestigious organizations have honored her work. She is a fellow of the American College of Surgeons (FACS) and Society of Surgical Oncology (FSSO). She is a member of the Society for Immunotherapy of Cancer, American Association of Cancer Research, Society for Melanoma Research, Connective Tissue Oncology Society, Association of Academic Surgeons, and Association of Women Surgeons.
She volunteers her time and expertise on behalf of the Melanoma Research Foundation, members of her community in need, STEM programs for girls, and other initiatives. She also is fellowship trained in Physician Wellness and Wellbeing and teaches somatic technique, mindfulness-based stress reduction, meditation, and breathwork. -
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
On Partial Leave from 05/16/2024 To 05/15/2025Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Michael Lim, M.D.
Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
Trigeminal neuralgia treatment: https://www.youtube.com/watch?v=-n8nvwkwZik
Trigeminal neuralgia patient stories: https://www.youtube.com/watch?v=kClePRPYlQs&t=1s -
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
-
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
Holden Maecker
Professor (Research) of Microbiology and Immunology
On Partial Leave from 09/15/2024 To 08/31/2025Current Research and Scholarly InterestsI'm interested in immune monitoring of T cell responses to chronic pathogens and cancer, and the correlation of T cell response signatures with disease protection.
-
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
David Miklos
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
-
Lori Muffly
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Muffly's interests include investigator initiated clinical trials focused on cellular therapies for adults with acute lymphoblastic leukemia and acute myeloid leukemia. She also has an active health outcomes research program focused on patterns of care and improving access to care for adults with acute leukemia.
-
Hiromitsu (Hiro) Nakauchi
Professor of Genetics (Stem Cell)
Current Research and Scholarly InterestsTranslation of discoveries in basic research into practical medical applications
-
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsOur labaratory focuses on the study of immune recognition by T and NK cells with special emphasis on graft vs host disease and graft vs tumor reactions. We utilize both murine and human systems in an effort to enhance graft vs tumor reactions while controlling graft vs host disease. We have developed bioluminescence models in collaboration with the Contag laboratory to study the trafficking of immune effector cells with a special emphasis on NK, T and regulatory T cells.
-
Derick Okwan
Assistant Professor of Pathology
Current Research and Scholarly InterestsBroadly, the Okwan lab’s primary interest is to understand how and why the immune system contributes to nearly all chronic diseases. The immune system of the modern human has evolved from a history of stress to the species: famines, continual bouts of lethal pandemics, as well as major climate/environmental and migratory changes that exposed the immune system to novel threats. At the forefront of these challenges are innate immune cells, particularly neutrophils, the most abundant leukocytes. For the first time in human history – at least in the western world- we live in an era of abundance. The Okwan lab is interested in understanding how this traumatic history creates a functional mismatch for the neutrophil, which we believe underpins their roles in chronic diseases of the modern era: cancer, cardiovascular disease, neurodegeneration, and autoimmune disorders. Rather than wholesale depletion of neutrophils and innate immune cells, we seek to identify novel approaches to leverage these cells to combat various diseases.
-
Peter Parham
Professor of Structural Biology and, by courtesy, of Microbiology and Immunology
Current Research and Scholarly InterestsThe Parham laboratory investigates the biology, genetics, and evolution of MHC class I molecules and NK cell receptors.
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program.
